Table 3.

Correlations of CCN expression levels with overall survival in primary ovarian carcinomas

Clinical characteristicsNo. death*/Total nMedian survival months (95% confidence interval)Log-rank test, P
Age
    <6514/29
    ≥6516/30
Stage
    I-II1/10NA0.0132
    III-IV27/4724.4 (18.4-30.3)
Grade
    1-24/1248.2 (14.5-48.2)0.1963
    324/4424.4 (13.8-33.4)
Differentiation
    Well + Mod4/1248.2 (14.5-48.2)0.1963
    Poor24/4424.4 (13.8-33.4)
Histopathologic type
    Serous papillary18/3324.4 (14.5-33.4)0.2568
    Others12/2630.3 (19.8-NA)
CCN2
    Negative16/3227.3 (18.4-NA)0.7419
    Positive14/2725.9 (14.5-48.2)
CCN1
    Negative8/2230.3 (24.4-NA)0.0979
    Positive22/3720.8 (12.1-33.4)
CCN4
    Negative25/5127.0 (18.4-NA)0.7305
    Positive5/824.3 (1.5-48.2)
CCN5
    Negative28/5425.9 (19.8-33.4)0.8426
    Positive2/5NA
CCN6
    Negative17/3727.0 (20.8-NA)0.1974
    Positive13/2225.9 (6.2-33.4)
Total no. positive markers
    0-113/2727.3 (13.8-NA)0.7136
    2 or more17/3225.9 (19.8, 48.2)
  • NOTE: The median follow-up time was 18.4 months.

    Abbreviation: NA, not available.

  • * Among the 59 patients, 30 died.

  • Statistically significant.